

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089815 A2

(51) International Patent Classification⁷: **A61K 31/573**,
9/08, 47/48

(21) International Application Number: **PCT/US02/13701**

(22) International Filing Date: **29 April 2002 (29.04.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/289,337 **7 May 2001 (07.05.2001)** **US**

(71) Applicant: **ALLERGAN, INC.** [—/US]; 2525 Dupont
Drive, Irvine, CA 92612 (US).

(72) Inventor: **LYONS, Robert, T.**; 27164 Woodbluff Road,
Laguna Hills, CA 92653-7533 (US).

(74) Agents: **FISHER, Carlos, A.** et al.; Allergan, Inc., 2525
Dupont Drive, Irvine, CA 92612 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **DISINFECTING AND SOLUBILIZING STEROID COMPOSITIONS**

(57) Abstract: Methods and ophthalmic compositions comprising a lipophilic drug in aqueous formulation with cyclodextrin or a cyclodextrin derivative.

WO 02/089815 A2

Disinfecting and Solubilizing Steroid Compositions

This application claims priority under 35 U.S.C. §119(e)(1) to provisional application number 60/289,337, filed May 7, 2001, which is hereby incorporated by reference herein.

Background of the Invention

The eye, like other parts of the central nervous system, has limited regeneration capability. Thus, many ocular diseases and injuries are difficult to treat. Presently, there are no truly effective treatments for, for example, retinal photic injury, retinal ischemia-induced eye injury, age-related macular degeneration, and free-radical-mediated diseases and/or injuries. Certain of these degenerations and injuries result in the irreversible destruction of the photoreceptor cells; therefore prophylaxis is the only viable option for management. Loss of vision also arises as a result of ischemia-reperfusion injury that is associated with retinal arterial occlusion, retinal venous occlusion, and glaucoma.

Many ocular degenerations are secondary to other primary compromising conditions, for example, diabetic retinopathy and lupus retinopathy. Corneal degenerations, for example, are usually not inherited, but occur in mid-life or later with lesions that are secondary to primary manifestations of aging, inflammation, trauma, and systemic disease.

The eye is also particularly vulnerable to infection caused by virulent bacteria. The most frequently encountered bacterial infections are believed to be bacterial keratitis, bacterial

conjunctivitis, and bacterial blepharitis. The most significant ocular viral infections are caused by the family of herpesviruses (HSV-1, HSV-2, varicella-zoster virus, cytomegalovirus, and Epstein-Barr virus.) Some ocular tissues (e.g., cornea, lens, and vitreous) are avascular with few mesenchymal cells and therefore are highly susceptible to infection. Ocular tissue already compromised due to degenerative injury (e.g., lesions) or physical trauma (e.g., laceration) affords easy entrance to bacteria and viruses. For example, infection can follow superficial or penetrating corneal injury, and the type of offending matter and the time between trauma and therapy are oftentimes determinative of the type and extent of infection. Fungal infection can be seen in surface injuries involving vegetable matter. Another competing consideration is the fact that certain therapeutic agents used to treat ocular injury and/or infection also suppress the host's immunologic defense mechanism, thus rendering the eye susceptible to other types of infections.

Ocular inflammation is a nonspecific result of tissue damage. While there are several agents that can elicit an inflammatory response, microbial (bacterial, viral, or fungal) infection and various immunologic conditions (e.g., hypersensitivity, allergy, and autoimmunity) are the most common causes of ocular inflammation. Inflammation associated with chemical and thermal injury can have a highly destructive outcome on the eye, and especially the cornea. Physical trauma to the cornea may be accompanied by intraocular inflammation, synechiae leading to glaucoma, and secondary membrane

formation. Collagen is the major structural protein of the cornea. The normal host response to inflammation produces polymorphonuclear (PMN) leukocytes or corneal fibroblasts which release matrix-destroying enzymes (e.g., collagenases), leading to the destruction of collagen. Also, normal corneal epithelium contains no latent or active collagenases. However, following chemical injury to the eye, these cells have been known to produce the destructive enzyme. Other macromolecules such as proteoglycans and other glycoproteins are also destroyed. Neovascularization is a sequela to the majority of ocular inflammatory responses. Chronic ocular inflammations such as trachoma and inflammation resulting from penetrating corneal injuries lead to scarring of the cornea. This is attributable to the enhanced production of collagen by corneal and conjunctival tissue fibroblasts as potentiated by the presence of inflammatory cells. Stromal scarring (e.g., from stromal edema) disturbs the ordering and spacing of collagen fibrils that are necessary to prevent light scattering, and causes a loss of stromal transparency.

The inflammatory response is a dominant aspect of corneal ulceration (ulcerative keratitis), which is a frequent cause of vision loss. Corneal ulceration has several causes, chiefly viral (e.g., Herpes simplex is the most common and is the leading cause of corneal blindness in the U.S.) or bacterial infection (*Pseudomonas* sp.), chemical (e.g., alkali burn) and thermal injury, and vitamin A and protein deficiencies. Enzymatic breakdown of collagen is the major degenerative aspect of the ulceration. The

outcome of ulceration, if untreated, is one or more of perforation of the cornea, formation of opaque scar tissue, and vascular invasion, with ultimate blindness. The inflammatory response is also at work in the corneal stroma in nonulcerative keratitis (also, interstitial keratitis), which has either bacterial, viral, or parasitic origin. Although less frequent than ulcerative bacterial keratitis, interstitial keratitis is a significant cause of visual impairment in developing countries, and the major causes of which are *T. pallidum* (the syphilis bacteria) and *Borrelia burgdorferi* (Lyme disease.)

Refractive surgical procedures aimed at altering corneal curvature for treating myopia and astigmatism, for example, result in a disruption of several corneal components, such as epithelial cells and their adhesion structures, the Bowman's layer and the anterior stroma. Incisional procedures (e.g., radial keratotomy (RK)) utilizing cutting implements invariably damage many layers of cells adjacent to the incision, and hence impair the wound-healing ability without attendant scar formation. The use of UV and non-UV emitting lasers in ocular surgery (e.g., excimer laser keratectomy, photorefractive keratectomy (PRK) and laser in-situ keratomileusis (LASIK)) has evolved to minimize the extent of cell disruption during excisional procedures and to enhance the wound-healing ability of the surgical site. However, despite the improvements of lasers over cutting implements, one of the main drawbacks of corrective laser procedures is the development of "corneal haze", or clouding, leading to light scattering. While many reasons have been postulated

as to why the haze develops, the chief theory is that the haze is a scar resulting from improper wound healing. Improper collagen repair and/or alignment, inflammation, and improper epithelial cell coverage of the cornea are believed to play a role in the scar formation. Another drawback of laser procedures is that they set into motion a cascade of free-radical mediated cellular injuries, such as DNA damage, enzyme inactivation, and lipid peroxidation, leading to corneal toxicity which may impact on wound healing and the development of post-operative corneal haze.

Numerous therapies and therapeutic agents have been developed over the years to treat sequelae of ocular degeneration, physical and chemical traumatic ocular injury, and ocular inflammation. While many of these have proven to be useful and provide an acceptable level of therapy and reparation to the damaged eye tissue, others have unacceptable side effects that dispose the already impaired/injured eye to further vulnerability (e.g., toxicity.) For example, corticosteroids have been used topically to reduce corneal scarring and inflammation. However their use is deemed controversial because they are known to enhance bacterial growth or recurrence of ulcers. Many antibiotics (e.g., beta-lactams and certain fluoroquinolones) are not well-tolerated, give rise to toxicities, or are of moderate efficacy.

The use of immunosuppressive agents in treating autoimmune ocular disease, e.g., uveitis, is controversial because of many serious side effects including bone marrow depression, thrombocytopenia, bleeding, nausea, vomiting, and stomatitis occur. Without attempting a comprehensive and exhaustive

list of agents that have proven beneficial in the management of primary and secondary sequelae of ocular degeneration, injury, surgical trauma, and attendant inflammation, representative classes of compounds include antibacterials (e.g., broad spectrum antibiotics), antivirals, non-steroidal antiinflammatory agents, steroids, collagenase inhibitors, cholinergics, cycloplegics, and wound healing modulators.

Among the agents which have been shown to have efficacy in the treatment of ocular inflammation are steroids including, without limitation, dexamethasone, prednisolone, prednisone, fluorometholone, betamethasone, and hydrocortisone. Many compounds having utility as therapeutic compounds for the treatment of ocular conditions, including many steroids, are hydrophobic compounds having little solubility in aqueous solution at roughly neutral pH values. While some such compounds have been formulated at pH values above or below the range from about 6.8 to about 7.8 in order to cause any ionizable groups to become charged, ophthalmic solutions or suspensions formulated at such values are usually irritating to the patient. Additionally, the resulting charged agent is less able to permeate the corneal epithelium than its uncharged counterpart, and is therefore less effective in delivering its therapeutic effect.

Methods for increasing the solubility of hydrophobic drugs have typically involved formulating the drug either as a suspension or in an emulsion. Given the short residence time of topically applied ophthalmic solutions, suspensions are of limited

usefulness in that they require the preparation of a saturated solution of the drug in which the compound in suspension cannot dissolve until the temperature of the solution increases or in which loss of the drug from solution by transport across the corneal epithelium permits more solid drug to dissolve. As both of these results take some time, the amount of solution lost in the meantime through tearing and by drainage through the lacrimal and naso-lacrimal ducts can be considerable and lead to decreased bioavailability of the therapeutic agent.

Emulsions comprise either oil-in-water or water-in-oil systems in which the hydrophobic therapeutic agent is dissolved in lipid globules suspended in an aqueous phase, or in an oil phase which surrounds suspended droplets of the aqueous phase, respectively. A common problem with most emulsions for topical ocular delivery of a therapeutic agent is that, they can cause ocular irritation and blurred vision for a time following application.

Relatively recently members of a class of barrel-shaped cyclic oligosaccharides called cyclodextrins have been shown to improve the physiochemical properties of certain drugs through the formation of inclusion complexes. Cyclodextrins (CDs) consist of 6, 7 or 8 glucose units; these cyclodextrins are termed alpha, beta or gamma cyclodextrins, respectively. Due to the architecture of the cyclodextrin molecule, the interior of the "barrel" is hydrophobic, which the exterior of the molecule is ionic. In certain cyclodextrin derivatives one or more glucose units may be substituted with various groups, such as

hydroxypropyl (HP) groups or sulfobutylether (SBE) groups. Such substitutions are usually found in the exterior of the CD molecule.

CDs have been shown to increase the aqueous solubility and stability of poorly water soluble drugs. See Loftssona et al., *Advanced Drug Delivery Reviews* 36:59-79 (1999); this and all references cited herein are hereby incorporated by referenced as part of this specification unless specifically excluded. Thus, the aqueous stabilities of the drugs pilocarpine, cetirizine, hydrocortizone and dexamethasone has been shown to have been increased by formulation of these drugs in combination with cyclodextrin derivatives.

Sequesterization of the drug within the barrel of the cyclodextrin molecule increases the solubility of the drug, however, therapeutic efficacy requires that the drug also be released from the CD effectively enough to permit the drug's passage through the corneal epithelium, since the CD-drug complex does not appear to permeate the cornea itself. For example, experimental evidence has demonstrated that complexation of pilocarpine with SBE4- β -CD, despite increasing solubility of pilocarpine in aqueous solution, renders the complex unable to penetrate the cornea. *Id.* at 70.

The amount of CD used for complexation must be kept as low as possible for toxicological, tonicity and bioavailability reasons. The use of water-soluble, therapeutically inert polymers such as polyvinylpyrrolidone (PVP) and cellulose derivatives such as hydroxypropylmethylcellulose (HPMC) as an aid in enhancing complex formation has been disclosed.

See *id.*; see also US Patent No. 5,324,718. Such enhancement of complex formation means that less CD can be used for the ophthalmic formulation ultimately used.

Optimal enhancement of complex formation using CD and polymers appears to require the application of heat at temperatures of 120° C or more. However, the very heat used to enhance solubility and complex formation can result in degradation and loss of stability of the drug. Thus, the drug is often added after the CD-polymer complex is formed, even though this results in an additional step in the process. See US Patent No. 5,324,718.

For these reasons new methods for preparing ophthalmic CD-polymer-drug complexes are needed. Once such method would protect and stabilize the active drug during exposure to high temperatures. Another such method would provide a high efficiency method of complex formation without the application of heat. Also, new self-stabilizing therapeutic compositions would be useful which compositions preserve the active drug while being complexed with CD and a water soluble polymer during autoclaving or other exposure to high temperature.

Summary of the Invention

The present invention is drawn to methods and compositions for stabilizing, solubilizing, and increasing bioavailability of a drug having low aqueous stability. In one embodiment the drug is

formulated as an topical ophthalmic solution having increased comfort and able to delivery the active drug so as to effectively provide a therapeutic effect. In a preferred embodiment the active drug is a steroid; in a particularly preferred embodiment the steroid is prednisolone.

The claimed ophthalmic compositions utilize cyclodextrins or cyclodextrin derivatives in complex with a drug, a water soluble polymer such as a cellulose derivative (e.g., methyl cellulose, hydroxypropylmethylcellulose) and a cationic buffer. Preferably the cationic buffer is an amine buffer and has a pKa in the slightly acidic range, e.g., about pH 5.0 to about 7.0, even more preferably about 6.0. The buffer is preferably selected from histidine or bis-tris buffers. Such a composition is capable of being formulated as a drug-CD inclusion complex at high heat with significantly reduced degradation and loss of stability than when the drug is formulated in an anionic buffer, such as phosphate buffer.

In another embodiment, the invention comprises forming such inclusion complexes by the ultrasonication of a solution comprising cyclodextrin, drug and an optional water soluble polymer. Such complexation can be done without the use of high heat, such as that provided by autoclaving. In this case any suitable common buffer (other than phosphate buffers) can be used, regardless whether they are cationic or anionic in the ionized form.

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment the present invention is drawn to methods for the formulation of lipophilic drugs for ophthalmic topical delivery using cyclodextrins as an aid to solubilizing such drugs in aqueous solution. Without limitation, such drugs may be chosen from those lipophilic drugs contained in the following listing: ciprofloxacin, ofloxacin, norfloxacin, cefazolin, tobramycin, gentamycin, an aminoglycoside, a penicillin, a semi-synthetic penicillin, amoxicillin, ampicillin, carbenicillin, ticarcillin, mezlocillin, a cephalosporin, vancomycin, chloramphenicol, erythromycin, clindamycin, rifampin, bacitracin, polymyxin, spectinomycin, a sulfonamide, trimethoprim, superoxide dismutase, astaxanthin, canthaxanthin, beta-carotene, zeaxanthin, lutein, alpha-tocopherol, ascorbic acid, glutathione, selenous acid, sodium selenate, acyclovir, ganciclovir, idoxuridine, vidarabine, trifluridine, bromovinyldeoxyuridine, azidothymidine, amantadine, rimantadine, dexamethasone, prednisolone, prednisone, fluorometholone, betamethasone, hydrocortisone, an alpha-hydroxyacid, a beta-hydroxyacid, an alpha-ketoacid, a beta-ketoacid, ketorolac, indomethacin, flurbiprofen, loxoprofen, diclofenac, atropine, pilocarpine, carbachol, physostigmine, phenylephrine, acetazolamide, timolol maleate, fibronectin and vitronectin as well as analogs or fragments thereof, acetyl cysteine, or mixtures thereof.

The cyclodextrins may be selected from naturally occurring cyclodextrins or their synthetic

derivatives. Cyclodextrins are cyclic oligosaccharides with hydroxyl groups on the outer surface and a void cavity in the center. Their outer surface is hydrophilic, and therefore they are usually soluble in water, but the cavity has a lipophilic character. The most common cyclodextrins are α -cyclodextrin, β -cyclodextrin and γ -cyclodextrin, consisting of 6, 7 and 8 α -1,4-linked glucose units, respectively. The number of these units determines the size of the cavity.

Some common cyclodextrin derivatives are, without limitation, formed by alkylation (e.g. methyl- and ethyl- β -cyclodextrin) or hydroxyalkylation of the hydroxyl groups (e.g. hydroxypropyl- and hydroxyethyl-derivatives of α -, β -, and γ -cyclodextrin) or by substituting the primary hydroxyl groups with saccharides (e.g. glucosyl- and maltosyl- β -cyclodextrin). Hydroxypropyl- β -cyclodextrin and its preparation by propylene oxide addition to β -cyclodextrin, and hydroxyethyl- β -cyclodextrin and its preparation by ethylene oxide addition to β -cyclodextrin, were described in a patent of Gramera et al. (U.S. Pat. No. 3,459,731, issued Aug. 1969) over 20 years ago. Cyclodextrin is normally present at a concentration of about 10% to about 30% by weight.

In certain embodiments the invention comprises, either optionally or as a mandatory component, a water soluble polymer as an aid in complex formation, present at from about 0.1% to about 5% by weight. Examples of such water soluble polymers include cellulose derivatives, polyvinyl pyrrolidone and the

like. When formulated a drug-CD-polymer complex may be formed at high heat (e.g., by autoclaving) in a cationic buffer such as an amine buffer. Such buffer may comprise, without limitation, a histidine buffer or a bis-tris buffer. This is particularly useful when formulating a steroid such a prednilosone. Buffer concentrations are in the range from about 10 to about 50 mM, preferably about 20 mM.

In another embodiment the invention comprises a method for forming drug-cyclodextrin complexes, either with or without a polymer, by ultrasonication, preferably with a high-energy probe sonicator. For larger scale lots high pressure, high cavitation ultrasonic homogenizers are commercially available and may be used.

A further embodiment of the invention comprises the use of a boric acid/sodium borate buffer system in conjunction with stabilized chlorine dioxide (e.g., the form of stabilized chlorine dioxide sold under the trade name Purite® by Allergan, Inc.) to safely and effectively preserve and increase the shelf life of cyclodextrin-based drug formulations. See International Patent Application Publication No. WO 00/12137, incorporated by reference herein.

The following Examples do not limit, but rather illustrate the invention, which is defined solely by the claims that conclude this specification.

EXAMPLES

Example 1

To optimize a cyclodextrin-based formulation for the ocular administration of soluble prednisolone acetate (PA), the following methods were used to evaluate ophthalmic formulations of PA and methods of making such formulations.

The complexation of five β -cyclodextrin (CD) derivatives with PA was evaluated, both with and without added cellulose polymer (HPMC). The β -cyclodextrins were: methyl- β -cyclodextrin, HP-CD and SBE-CD, with the latter being substituted by an average of either 12, 7, or 4 groups per molecule.

Methods of making inclusion complexes were: (I) rapid stirring at 25°C for 72 hrs, (II) high-shear processing at 60°C with a rotor/stator homogenizer, (III) brief ultrasonication with a high-energy probe sonicator, and (IV) autoclaving in sealed borosilicate glass vials for 10 min at 121°C. In every case, an equimolar concentration of PA was added to 10% solutions of CD in dilute (20 mM) aqueous buffer prior to complex formation. After processing, aliquots were filtered (0.45 μ m) for HPLC analysis of soluble, complexed PA and the hydrolytic degradant, non-esterified prednisolone (P).

The formulations were as follows:

<u>Ingredient</u>	<u>Grams / 100 mL</u>
Cyclodextrin	10.0
HPMC	0.5
Prednisolone acetate	0.5
Boric Acid	0.6

Na borate	0.035
Purite	0.005
HCl	adjust to pH 7

Results were as follows. Among tested β -CD derivatives, methyl was by far the most efficient solubilizer (PA/CD molar ratio). Although only 40% as effective, hydroxypropyl (HP) had a superior toxicity profile. Affinity of sulfobutyl ether CD for PA increased as degree of substitution was reduced (12, 7, 4), but was never as high as HP.

Observed complexation efficiency for each method was as follows: IV > II = III > I. During autoclaving, complexation was enhanced by about 70% (to 4.6 mg/mL) in the presence of 0.1% hydroxypropylmethyl cellulose (HPMC), but not by other tested polymers. Autoclave stress allowed quick screening for buffer catalysis of PA hydrolysis. It was found that phosphate salts accelerated hydrolysis by about 16-fold compared to acetate buffer or no-buffer control.

Example 2

Prednisolone acetate (PA) is solubilized with a 5% excess of either hydroxypropyl (HP) β -cyclodextrin (CD) or sulfobutyl ether 4 (SBE4) β -cyclodextrin in the presence of hydroxypropylmethyl cellulose (HPMC). SBE4, with an average molecular substitution of four, is the preferred derivative due to a higher binding capacity for PA and a lower contribution to ionic

strength. HPMC serves both to increase solution viscosity and enhance stability of the drug-CD complex. In order to minimize rates of PA hydrolysis and maintain patient comfort, the solution is adjusted to pH 6 using a 20 mM histidine buffer system. Buffer salts with high electron density, such as phosphate, are avoided since these appear to catalyze PA hydrolysis.

A preferred formulation is as follows:

<u>Ingredient</u>	<u>Grams / 100 mL</u>
Cyclodextrin	10.0
HPMC	0.5
Prednisolone acetate	0.5
Histidine (20 mM)	
PHMB (1 ppm)	
HCl	adjust to pH 6.0

This formulation is autoclaved in sealed borosilicate glass vials for 10 min. at 121°C to enhance complex formation, then cooled to room temperature before aliquots are taken for HPLC analysis of complexed drug and any degradation products.

The results indicate that this formulation is more effective at stabilizing the prednisolone and preventing degradation when complexes are formed at high temperature than the formulation of Example 1. Key elements are formulation at pH below about 7.0 and use of a cationic buffer, in this case histidine.

Other embodiments of the invention are disclosed
in the following claims.

CLAIMS

What is claimed is:

1. An aqueous ophthalmic composition comprising a lipophilic drug, a cationic buffer, and an optional water soluble polymer formulated within the range of about pH 5.5 to about 7.0.
2. The aqueous composition of claim 1 wherein said cationic buffer is selected from the group consisting of histidine and bis-tris.
3. The aqueous composition of claim 2 wherein the cationic buffer is histidine.
4. The composition of any of claims 1-3 wherein said drug is prednisolone.
5. A method of making an inclusion complex comprising a lipophilic drug, a cyclodextrin or cyclodextrin derivative, and a water soluble polymer comprising:
 - a) mixing said drug, cyclodextrin or cyclodextrin derivative and polymer in a cationic buffer having a pKa below about 7.0, and
 - b) heating the mixture of step a) to a temperature in the range of about 100 to about 140°C for between about 5 minutes and about 30 minutes.

6. The method of claim 5 wherein said cyclodextrin derivative is a SBE cyclodextrin.
7. The method of claim 5 wherein said buffer is an amine buffer.
8. The method of claim 7 wherein said buffer is histidine.
9. The method of claim 8 wherein said buffer is bis-tris.
10. The method of any of claims 5-9 wherein said drug is prednilosone.
11. A ophthalmic prednilosone composition according to any embodiment disclosed in the specification.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089815 A3

(51) International Patent Classification⁷: **A61K 31/573**,
9/08, 47/48, 31/57

(21) International Application Number: PCT/US02/13701

(22) International Filing Date: 29 April 2002 (29.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/289,337 7 May 2001 (07.05.2001) US

(71) Applicant: **ALLERGAN, INC.** [—/US]; 2525 Dupont
Drive, Irvine, CA 92612 (US).

(72) Inventor: **LYONS, Robert, T.**; 27164 Woodbluff Road,
Laguna Hills, CA 92653-7533 (US).

(74) Agents: **FISHER, Carlos, A.** et al.; Allergan, Inc., 2525
Dupont Drive, Irvine, CA 92612 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
20 February 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: DISINFECTING AND SOLUBILIZING STEROID COMPOSITIONS

(57) Abstract: Methods and ophthalmic compositions comprising a lipophilic drug in aqueous formulation with cyclodextrin or a cyclodextrin derivative.

WO 02/089815 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/13701

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/573 A61K9/08 A61K47/48 A61K31/57

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 504 113 A (LUCERO JASMIN C) 2 April 1996 (1996-04-02) column 3, line 14 - line 15 column 3, line 35 - line 50 column 5, line 11 - line 20 ---	1-3,11
X	EP 0 824 916 A (SANTEN PHARMA CO LTD) 25 February 1998 (1998-02-25) page 2, line 44 - line 58; examples ---	1,11
X	US 5 744 154 A (PAGES BERNARD ET AL) 28 April 1998 (1998-04-28) column 1, line 41 - column 2, line 4; examples 1,2 --- -/--	1,11

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

4 December 2002

Date of mailing of the international search report

19/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/13701

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 18316 A (ALCON LAB INC ;SARKAR RUMA (US); SINGH ONKAR N (US); WEINER ALAN L) 6 April 2000 (2000-04-06) page 2, line 24 - line 28 page 3, line 20 - line 25 page 5, line 14 - line 23; claims 1-4,7,9-12,15-17; examples 1,2,5; tables 6,7 -----	1,11
X	US 4 518 608 A (KAHAN AGOSTNE) 21 May 1985 (1985-05-21) column 2, line 50 -column 3, line 16 column 3, line 45 - line 55; claims 1,2,5 -----	1,2,11
X	EP 0 958 836 A (MENICON CO LTD) 24 November 1999 (1999-11-24) page 2, line 37 - line 40 page 6, line 37 - line 43; claims 1,2,6,8,9,11; example 2; tables 4,5 -----	1,2,11
X	US 4 829 083 A (DOULAKAS JOHANN) 9 May 1989 (1989-05-09) column 1, line 64 -column 2, line 20; example 4 -----	1,4,11
A	EP 0 579 435 A (LOFTSSON THORSTEINN) 19 January 1994 (1994-01-19) cited in the application page 4, line 5 - line 19 page 5, line 8 - line 48; claims 1,16,17,19; examples 1-8,11,13 -----	5-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 02/13701

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Present claims 1, 5 and 6 relate to an extremely large number of possible compounds, namely a lipophilic drug and a cationic buffer, so that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. The term "lipophilic drug" defines the active agent by its solubility in lipids. However, a compound cannot be sufficiently characterised by its solubility in lipids, because it is impossible to know which compounds are encompassed in this expression. Moreover a lack of clarity arises due to the inconsistency between the expression "lipophilic drug" and the compounds listed on page 11 of the description. Several compounds in this list, such as ascorbic acid, glutathione and sodium selenate are freely soluble in water. A lack of clarity also arises due to the inconsistency between the expression "cationic buffer" and the compounds listed in claims 2, 3, 8 and 9. The buffers histidine and bis-tris are zwitterionic buffers, having both a positive and a negative charge.

Consequently, the search has been carried out for those parts of the application which do appear to be clear, namely the compounds mentioned in the examples and in claims 2-4, and 7-10 and those mentioned in the description on page 10, lines 15-16 and the concepts of "lipophilic drug" and "cationic buffer".

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/13701

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5504113	A	02-04-1996	US 5658948 A	19-08-1997
EP 0824916	A	25-02-1998	JP 3170619 B2	28-05-2001
			JP 8291065 A	05-11-1996
			AT 196846 T	15-10-2000
			DE 69610622 D1	16-11-2000
			DE 69610622 T2	31-05-2001
			DK 824916 T3	05-02-2001
			EP 0824916 A1	25-02-1998
			GR 3034705 T3	31-01-2001
			US 6281224 B1	28-08-2001
			ES 2152016 T3	16-01-2001
			WO 9632941 A1	24-10-1996
			PT 824916 T	31-01-2001
US 5744154	A	28-04-1998	FR 2738149 A1	07-03-1997
			AT 163851 T	15-03-1998
			CA 2183367 A1	07-03-1997
			DE 69600185 D1	16-04-1998
			DE 69600185 T2	16-07-1998
			EP 0761217 A1	12-03-1997
			JP 9165334 A	24-06-1997
			DK 761217 T3	28-09-1998
			ES 2116811 T3	16-07-1998
WO 0018316	A	06-04-2000	AU 6057199 A	17-04-2000
			BR 9913955 A	12-06-2001
			CA 2345466 A1	06-04-2000
			EP 1115406 A2	18-07-2001
			WO 0018316 A2	06-04-2000
US 4518608	A	21-05-1985	HU 185926 B	28-04-1985
			BE 885441 A1	16-01-1981
			CA 1177398 A1	06-11-1984
			DE 3036367 A1	16-04-1981
			DK 408780 A	28-03-1981
			FI 803043 A	28-03-1981
			FR 2466248 A1	10-04-1981
			GB 2059768 A ,B	29-04-1981
			IL 61308 A	29-06-1984
			IT 1195313 B	12-10-1988
			JP 56073023 A	17-06-1981
			NL 8005357 A	31-03-1981
			PL 226938 A1	16-10-1981
			SE 8006560 A	28-03-1981
			SU 1175350 A3	23-08-1985
			YU 243980 A1	30-04-1983
EP 0958836	A	24-11-1999	JP 2000047156 A	18-02-2000
			EP 0958836 A2	24-11-1999
			US 6121327 A	19-09-2000
US 4829083	A	09-05-1989	DE 3612538 A1	15-10-1987
			CA 1306684 A1	25-08-1992
			DK 157987 A ,B,	15-10-1987
			EP 0243308 A2	28-10-1987
			HK 26294 A	31-03-1994
			JP 2040738 C	28-03-1996

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/13701

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 4829083	A	JP 7074162 B	09-08-1995	
		JP 62242618 A	23-10-1987	
		SG 13094 G	10-06-1994	

EP 0579435	A	19-01-1994	US 5324718 A	28-06-1994
			AT 177647 T	15-04-1999
			DE 69323937 D1	22-04-1999
			DE 69323937 T2	23-09-1999
			DK 579435 T3	11-10-1999
			EP 0579435 A1	19-01-1994
			ES 2132190 T3	16-08-1999
			GR 3030345 T3	30-09-1999
			SG 49182 A1	18-05-1998
			US 5472954 A	05-12-1995

This Page Blank (uspto)